Related Experiment Video
Updated: Jul 2, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Anidulafungin: a drug evaluation of a new echinocandin
Jomy M Joseph1, Rose Kim, Annette C Reboli
1University of the Sciences in Philadelphia, Philadelphia College of Pharmacy, Philadelphia, PA 19104, USA.
Background:
Over the past two decades, the frequency and type of invasive fungal infections have increased greatly and thus have driven the need for new antifungal agents. Anidulafungin is the newest addition to the echinocandin armamentarium.
Objective:
The intention of this review is to provide a drug evaluation of anidulafungin, including its spectrum of activity, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse event profile, and its role in the treatment of invasive candidiasis.
Methods:
A PubMed search was performed to gather the most current and pertinent articles.
Conclusions:
Clinical trials have demonstrated anidulafungin's efficacy and tolerability in invasive candidiasis. Anidulafungin is not associated with any drug-drug interactions and does not require dosage adjustment in patients with renal and/or hepatic impairment.
Related Concept Videos
Antifungal Agents
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Anthelminthic Agents

